
Duramycin-LC-Biotin Conjugate Cat # D-1003

Product Description: \triangle Biotin is attached to amino groups of duramycin via a 6-carbon aminohexanoyl spacer. The conjugate contains 1 biotin molecule per duramycin molecule. Duramycin binds phosphatidylethanolamine (PE) at a 1:1 ratio with high affinity (K_d of 4-6 nM) and exclusive specificity.

Properties of Duramycin-LC-Biotin: The structure and physical properties of the conjugate are shown in Fig 1 and Table 1 below.



ØatÁFKÁÔ@^{a&adpÁnd*&c`¦^Á

Property	Specification
TYÁ	OÉHÍGÁ
O∏] ^ælæ) &^Á	Ô[[¦ ^∙•Ár[ããÁ

Væà|^ÁFKÁÚ¦[]^¦œã\∙Á

Catalog #	Product Name	Size/Dose	Price (USD)
ÖËF€€HÁ	Ö`¦æ(^&3)EŠÔË Óa[o3)Á	F €€ Á*¦æ{•BHOĐĚÁ;{[^•Á	ÅGHÌÈE€Á
		Δ	

Product Formulation Procedure MAdd 212uL of a solution of 5% DMSO in water to the vial and pipet up and down to dissolve the solid and obtain a 200uM stock solution in water containing 5% DMSO.

Ü^-△¦^} &^ḤÁ

•Á Ùœ-[¦åÁRPĒV@¦]^ÁÚÒÁÇŒFFŒMncreased Exposure of Phosphatidyllethanolamine on the Surface of Tumor Vascular Endothelium⊞e^[]|æ ãæÉA

FHÉA ĒGJJËHĒ Á

... ②[¦Á;¦c@;¦Ásj-{¦{ accā[}}Á;¦Ás[Á;|ac&?Áse)Á;¦å^¦Á;|^æ•^Ás[}cæ&cÁÖ¦ÈÁÓ¦ãe)ÁŐ¦æêÁs^Á*{ acā|Más¦ãe)*¦æêΟ { cac!*^dòS[{ Á;¦Á;@}}^M\$,F∈ЁHÌЁJHÌÁÁ



MOLECULAR TARGETING TECHNOLOGIES, INC.

ÌH-KŠā, &[|}ÁOĒ,^ÈĒV),ãóÅ ; H-KŠā, &[]ÁOĒ, ÈĒVDĀ.]HÌ€Á ; HĒJDÌKÂ, F€Ē, HÌĒ, JHÌKWWAÂ, F€Ē, HÌĒ, JGÌÁ

. M. (1995) | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1995 | 1